The Journal of Thoracic and Cardiovascular Surgery
Volume 133, Issue 1 , Pages 37-43 , January 2007

Roles of cyclooxygenase-2 and phosphorylated Akt (Thr308) in cardiac hypertrophy regression mediated by left-ventricular unloading

  • Jeremias Wohlschlaeger, MD

      Affiliations

    • Department of Pathology and Neuropathology, University Hospital Essen, University of Duisburg-Essen, Germany
    • J. W. and K. J. S. contributed equally to the study.
    • ,
  • Klaus Jürgen Schmitz, MD

      Affiliations

    • Department of Pathology and Neuropathology, University Hospital Essen, University of Duisburg-Essen, Germany
    • J. W. and K. J. S. contributed equally to the study.
    • ,
  • Jenci Palatty

      Affiliations

    • Department of Pathology and Neuropathology, University Hospital Essen, University of Duisburg-Essen, Germany
    • ,
  • Atsushi Takeda, MD

      Affiliations

    • Faculty of Health Science, School of Physical Therapy, Gumma Paz College, Gumma, Japan
    • ,
  • Nobuakira Takeda, MD

      Affiliations

    • Department of Internal Medicine, Jikei University, Tokyo, Japan
    • ,
  • Christian Vahlhaus, MD

      Affiliations

    • Department of Cardiology and Angiology, University Hospital Münster, Germany
    • ,
  • Bodo Levkau, MD

      Affiliations

    • Division of Pathophysiology, Department of Internal Medicine, University Hospital Essen, University of Duisburg-Essen, Germany
    • ,
  • Jörg Stypmann, MD

      Affiliations

    • Department of Cardiology and Angiology, University Hospital Münster, Germany
    • ,
  • Christof Schmid, MD

      Affiliations

    • Department of Thoracic and Cardiovascular Surgery, University Hospital Münster, Germany.
    • ,
  • Kurt Werner Schmid, MD

      Affiliations

    • Department of Pathology and Neuropathology, University Hospital Essen, University of Duisburg-Essen, Germany
    • ,
  • Hideo Andreas Baba, MD

      Affiliations

    • Department of Pathology and Neuropathology, University Hospital Essen, University of Duisburg-Essen, Germany
    • Corresponding Author InformationReprint requests: Hideo Andreas Baba, MD, Institute of Pathology, University Hospital of Essen, University of Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany

Received 10 May 2006 ,Revised 29 June 2006 ,Accepted 31 July 2006.

References 

  1. van EV, De Windt LJ. Myocyte hypertrophy and apoptosis: a balancing act. Cardiovasc Res. 2004;63:487–499
  2. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med. 2001;345:1435–1443
  3. Frazier OH, Benedict CR, Radovancevic B, Bick RJ, Capek P, Springer WE, et al. Improved left ventricular function after chronic left ventricular unloading. Ann Thorac Surg. 1996;62:675–681
  4. Baba HA, Grabellus F, August C, Plenz G, Takeda A, Tjan TD, et al. Reversal of metallothionein expression is different throughout the human myocardium after prolonged left-ventricular mechanical support. J Heart Lung Transplant. 2000;19:668–674
  5. Razeghi P, Taegtmeyer H. Activity of the Akt/GSK-3beta pathway in the failing human heart before and after left ventricular assist device support. Cardiovasc Res. 2004;61:196–197
  6. Zafeiridis A, Jeevanandam V, Houser SR, Margulies KB. Regression of cellular hypertrophy after left ventricular assist device support. Circulation. 1998;98:656–662
  7. Wohlschlaeger J, Schmitz KJ, Schmid C, Schmid KW, Keul P, Takeda A, et al. Reverse remodeling following insertion of left ventricular assist devices (LVAD): a review of the morphological and molecular changes. Cardiovasc Res. 2005;68:376–386
  8. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A. 2002;99:13926–13931
  9. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem. 1996;271:33157–33160
  10. Schmedtje JF, Ji YS, Liu WL, DuBois RN, Runge MS. Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J Biol Chem. 1997;272:601–608
  11. Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 1996;93:704–711
  12. Wong SC, Fukuchi M, Melnyk P, Rodger I, Giaid A. Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure. Circulation. 1998;98:100–103
  13. Liu W, Reinmuth N, Stoeltzing O, Parikh AA, Tellez C, Williams S, et al. Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways. Cancer Res. 2003;63:3632–3636
  14. Toker A, Cantley LC. Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature. 1997;387:673–676
  15. Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology. 2003;38:756–758
  16. Dorn GW, Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest. 2005;115:527–537
  17. LaPointe MC, Mendez M, Leung A, Tao Z, Yang XP. Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse. Am J Physiol Heart Circ Physiol. 2004;286:H1416–H1424
  18. Zhang Z, Vezza R, Plappert T, McNamara P, Lawson JA, Austin S, et al. COX-2-dependent cardiac failure in Gh/tTG transgenic mice. Circ Res. 2003;92:1153–1161
  19. Delgado RM, Nawar MA, Zewail AM, Kar B, Vaughn WK, Wu KK, et al. Cyclooxygenase-2 inhibitor treatment improves left ventricular function and mortality in a murine model of doxorubicin-induced heart failure. Circulation. 2004;109:1428–1433
  20. Razeghi P, Bruckner BA, Sharma S, Youker KA, Frazier OH, Taegtmeyer H. Mechanical unloading of the failing human heart fails to activate the protein kinase B/Akt/glycogen synthase kinase-3beta survival pathway. Cardiology. 2003;100:17–22
  21. Baba HA, Stypmann J, Grabellus F, Kirchhof P, Sokoll A, Schafers M, et al. Dynamic regulation of MEK/Erks and Akt/GSK-3beta in human end-stage heart failure after left ventricular mechanical support: myocardial mechanotransduction-sensitivity as a possible molecular mechanism. Cardiovasc Res. 2003;59:390–399
  22. Lecomte M, Laneuville O, Ji C, DeWitt DL, Smith WL. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J Biol Chem. 1994;269:13207–13215
  23. Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest. 2001;119:39S–63S
  24. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 2001;15:2057–2072
  25. Capone ML, Tacconelli S, Sciulli MG, Grana M, Ricciotti E, Minuz P, et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation. 2004;109:1468–1471
  26. Tessner TG, Muhale F, Riehl TE, Anant S, Stenson WF. Prostaglandin E2 reduces radiation-induced epithelial apoptosis through a mechanism involving AKT activation and bax translocation. J Clin Invest. 2004;114:1676–1685
  27. Han C, Wu T. Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J Biol Chem. 2005;280:24053–24063

 This study was supported by the Deutsche Forschungsgemeinschaft to H. A. Baba (Ba1730/9-1), C. Schmid, and C. Vahlhaus (Va156/5-2).

PII: S0022-5223(06)01701-6

doi: 10.1016/j.jtcvs.2006.07.042

The Journal of Thoracic and Cardiovascular Surgery
Volume 133, Issue 1 , Pages 37-43 , January 2007

Article Tools

* Image Usage & Resolution